wallstreet:online
 42,10EUR | -0,95 EUR | -2,21 %
Push-Kurse aus |
| Registrieren | Login
DAX-0,17 % EUR/USD+0,42 % Gold-0,13 % Öl (Brent)-1,19 %

Lineage Cell TherapeuticsAktie

ISIN: US53566P1093 | WKN: A2PP89 | Symbol: LCTX
0,978
 
USD
18.10.19 AMEX
+5,14 %
+0,048 USD
Geldkurs 18.10.19
0,945 USD
200 Stk.
Briefkurs 18.10.19
1,150 USD
1.700 Stk.
Mehr Daten anzeigen

Lineage Cell Therapeutics Chart

Neuigkeiten zur Lineage Cell Therapeutics Inc Aktie

ZeitTitel
11.09.19

Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
05.09.19

Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019
04.09.19

Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells
03.09.19

Lineage Cell Therapeutics Announces Data From Vision Restoration Program Published in Stem Cells and Development Journal
26.08.19

Lineage Cell Therapeutics Announces Issuance of U.S. Patent for System for Generating Immunogenic Dendritic Cells
20.08.19

Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019
15.08.19

Avatar R-BgO schrieb:
LineAge Cell Therapy
13.08.19

Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program
12.08.19

Lineage Cell Therapeutics Launches New Corporate Brand
08.08.19

BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update
01.08.19

BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
31.07.19

BioTime Announces Name Change to Lineage Cell Therapeutics
11.07.19

BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
02.07.19

BioTime Conducts Sale of Shares in OncoCyte Corporation
18.03.14

Avatar dottore schrieb:
Heute die Meldung pasend zum Kursknick BioTime Reports Q4 Loss Per Share Of $0.35 Vs. …
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Die neusten Nachrichten zu Lineage Cell Therapeutics

ZeitTitel
11.09.19
Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
05.09.19
Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019
04.09.19
Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells
03.09.19
Lineage Cell Therapeutics Announces Data From Vision Restoration Program Published in Stem Cells and Development Journal
26.08.19
Lineage Cell Therapeutics Announces Issuance of U.S. Patent for System for Generating Immunogenic Dendritic Cells
mehr Lineage Cell Therapeutics Nachrichten »

Nachrichten aus der Branche Biotechnologie

ZeitTitel
01:45 Uhr
Alexion Receives FDA Approval for ULTOMIRIS (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
18.10.19
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
18.10.19
BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert
18.10.19
BioNano Genomics: Was für Kurskapriolen!
18.10.19
Biotech Report: Breite Konsolidierung im Sektor
mehr Branchennachrichten »

Diskussionen zur Lineage Cell Therapeutics Aktie

ZeitTitel
15.08.19
6
BioTime

Indexzugehörigkeit von Lineage Cell Therapeutics

WertpapierPerf. %
Russell 2000 (calculated by Bridge Data Services)
-0,38
Nasdaq DM Ex Korea Small Cap GBP Index Net Total Return
+0,38
Nasdaq DM Ex Korea Small Cap Index Net Total Return
+0,67
Nasdaq DM Ex Korea Small Cap JPY Index Net Total Return
+0,51
NYSE American Composite Healthcare Subsector Index
+0,61
Nasdaq US Small Cap Value Index Net Total Return
+0,98
Nasdaq DM Ex Korea Small Cap GBP Index
+0,38
Nasdaq DM Ex Korea Small Cap EUR Index Net Total Return
+0,07
Nasdaq DM Ex Korea Small Cap EUR Index
+0,07
Nasdaq DM Ex Korea Small Cap CAD Index Net Total Return
+0,19
Alle zugehörigen Indizes »

Aktienkurs Lineage Cell Therapeutics A2PP89 |

BörsenplatzAMEX
Letzter Kurs0,978USD
Performance+5,14 %
Kurszeit18.10.19
Eröffnung0,950USD
Tageshoch0,980USD
Tagestief0,950USD
Vortageskurs0,930USD
Volumen38,30 Tsd.Stk.
52-Wochen Hoch2,150USD
52-Wochen Tief0,661USD
Anzahl Trades148
Performance 1 Monat-7,00 %
Performance 1 Jahr-53,96 %

Stammdaten zu Lineage Cell Therapeutics

NameLineage Cell Therapeutics Inc
KurznameLineage Cell
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2PP89
SymbolLCTX
BrancheBiotechnologie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl149,64 Mio.
Marktkapitalisierung146,32 Mio.USD

Performance Lineage Cell Therapeutics Aktie

ZeitKursPerf.
1 Tag0,978USD
+5,14 %
1 Woche0,950USD
-2,11 %
1 Monat1,000USD
-7,00 %
3 Monate1,130USD
-17,70 %
6 Monate1,250USD
-25,60 %
Lfd. Jahr0,913USD
+1,86 %
1 Jahr2,020USD
-53,96 %
3 Jahre3,540USD
-73,73 %
5 Jahre3,035USD
-69,36 %
10 Jahre4,299USD
-78,37 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameLineage Cell Therapeutics Inc
StadtAlameda
LandUSA USA
Webseitewww.biotimeinc.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Cerus Corporation
+0,45
2.
Edap TMS
+1,53
3.
Evotec
-1,42
4.
Halozyme Therapeutics
-3,45
5.
Silvercorp Metals
+0,57
6.
General Moly
-9,31
7.
Ballard Power Systems
+6,21
8.
Coeur Mining
+1,67
9.
Choom Holdings
-4,20
10.
Venzee Technologies
0,00